Stryker (SYK) DIvidends Date & History

Key Takeaways

• Stryker offers a current dividend yield of 1.07% with an annual payout of $3.52 per share.
• The company has raised its dividend for 32 consecutive years, averaging 7.6% annual growth over the past five years.
• A trailing payout ratio of 40.5% indicates strong sustainability, well-covered by earnings and free cash flow.
• Quarterly dividends of $0.88 per share, with the most recent ex-dividend date on March 31, 2026.
• Levered free cash flow of $4.17 billion (TTM) provides robust coverage for ongoing payments.
• Modest yield appeals to dividend growth investors in the medical devices sector.

Dividend Overview

Stryker Corporation (SYK), a leading medical technology firm, maintains a quarterly dividend policy with a current payment of $0.88 per share, equating to $3.52 annually. This delivers a yield of 1.07% based on a recent stock price around $329. The company is classified as a dividend growth stock rather than a high-yield play, prioritizing consistent increases over high current income. Payments occur quarterly, with the latest ex-dividend date on March 31, 2026, and payment on April 30, 2026. This profile suits investors seeking reliable, growing income from a stable healthcare leader focused on orthopaedics, MedSurg, and neurotechnology products.

Dividend History and Growth

Stryker has a exemplary record of dividend growth, achieving 32 consecutive annual increases. The quarterly dividend has risen steadily, from lower levels in prior decades to the current $0.88. Over the past five years, dividends per share have grown at a compound annual rate of approximately 7.6%, reflecting the company's commitment to returning value to shareholders. This consistency stems from robust operational performance and a long-term strategy balancing reinvestment in innovation with shareholder rewards. No cuts have occurred in over three decades, underscoring payment reliability amid industry cycles.

Dividend Sustainability and Payout Ratio

Stryker's dividend appears highly sustainable, supported by a trailing payout ratio of 40.5%—well below levels that signal risk. Earnings per share (EPS, trailing twelve months) stand at $8.39, comfortably covering the $3.52 annual dividend. Free cash flow (levered, TTM) of $4.17 billion far exceeds dividend obligations, with an estimated FCF payout around 31%. Debt levels are manageable, with total debt at $16.36 billion against $4.1 billion in cash and a debt-to-equity ratio of 73%. Strong operating cash flow of $5.04 billion and profit margins of 12.9% further bolster financial stability for continued payments.

Dividend Compared to Industry Peers

In the medical devices sector, Stryker's 1.07% yield is modest compared to peers like Medtronic (MDT) at around 3.3% and Abbott Laboratories (ABT) near 1.9%, which offer higher income but potentially slower growth. Closer rivals such as Zimmer Biomet (ZBH) yield about 1.05%, while growth-oriented firms like Boston Scientific (BSX) and Edwards Lifesciences (EW) pay no dividends. SYK's profile stands out for its growth streak and low payout, positioning it favorably for long-term income investors versus higher-yield but riskier options.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities—streamlining analysis beyond manual screening. Explore it to uncover hidden gems like reliable dividend payers in healthcare.

Is This Stock Attractive for Dividend Investors?

Stryker appeals to dividend growth investors prioritizing steady increases over high yields, given its 32-year streak and 7.6% five-year growth rate. Conservative investors may value the low 40.5% payout ratio and ample free cash flow coverage, signaling resilience in the cyclical medical devices industry. Long-term holders focused on healthcare innovation could find the modest 1.07% yield a solid base, complemented by potential capital appreciation from Stryker's leadership in orthopaedics and neurotechnology. However, income seekers chasing 3%+ yields might look elsewhere, as SYK emphasizes reinvestment for expansion. Overall, it suits patient portfolios balancing growth and reliability, though sector risks like regulatory changes warrant monitoring.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations